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Abstract
The molecular mechanisms underlying progressive liver fibrosis following surgical treatment of biliary atresia
(BA) remain unclear. Our aim was to address hepatic gene and protein expression and serum levels of matrix
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) after successful portoenterostomy (PE), and
relate them to histological signs of liver injury, clinical follow-up data and biochemical markers of hepatic
function. LIver biopsies and serum samples were obtained from 25 children after successful PE at median age
of 3.3 years. Serum MMP concentrations were determined by enzyme-linked immune sorbent assay. Hepatic
gene expression of MMPs and TIMPs was analyzed using real-time reverse-transcription PCR. Liver expression
of MMP-7 and cytokeratin-7 was studied using immunohistochemistry. Despite effective clearance of bio-
chemical and histological cholestasis following PE, BA patients showed increased hepatic gene expression of
MMP-7 (29-fold, p<0.001), MMP-2 (3.1-fold, p< 0.001), MMP-14 (1.7-fold, p50.007), and TIMP-1 (1.8-
fold, p< 0.001), when compared to controls. Similar to a biliary epithelial marker cytokeratin-7, expression of
MMP-7 localized in biliary epithelium of bile ducts and ductal proliferations and periportal hepatocytes and
was increased (p< 0.001) in relation to controls. BA patients had 6-fold higher serum levels of MMP-7
(p< 0.001), which correlated positively with hepatic MMP-7 gene (r50.548, p5 0.007) and protein
(r5 0.532, p5 0.007) expression. Patients showed a positive correlation between biliary MMP-7 expression
and Metavir fibrosis stage (r5 0.605, p5 0.001) and portal fibrosis grade (r5 0.606, p50.001). Neither
similarly increased MMP-7 expression nor correlation with liver fibrosis was observed in patients with intesti-
nal failure-associated liver disease and comparable Metavir stage. In conclusion, our findings support an
unique role of altered hepatic expression of MMP-7 in the progression of liver fibrosis after successful PE and
introduce a potential therapeutic target to pharmacologically extend native liver survival by inhibiting MMP-7
hyperactivity. Serum MMP-7 may be a valuable postoperative prognostic tool in BA.
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Introduction
Biliary atresia (BA) is a progressive obliterative
fibroinflammatory cholangiopathy of infancy and the
leading indication for paediatric liver transplantation
(LTx) worldwide [1]. The aetiology of BA is
believed to be multifactorial. Viral infections, envi-
ronmental factors or developmental defects may lead
to bile duct injury and rapidly progressing liver fibro-
sis [2]. The first line surgical treatment is portoenter-
ostomy (PE), which is considered successful when
patients achieve normal serum bilirubin concentration
below 20 mmol/L [1]. Despite successful PE, around
80% of the patients require LTx before adulthood
due to progressive liver fibrosis [2–4]. The molecular
mechanisms underlying this progressive liver injury
after successful PE remain unclear.
In cholestatic liver fibrogenesis, activated hepatic
stellate cells and portal myofibroblasts are thought to
serve as the major producers of excessive extracellu-
lar matrix, while bile ductules proliferate in a
deformed manner originating from pre-existing chol-
angiocytes, hepatocyte-to-cholangiocyte metaplasia,
or liver progenitor cells [5–7]. The epithelial cells of
bile ducts and proliferating ductules may function as
key drivers of fibrogenesis in BA by epithelial-to-
mesenchymal transition [6,8–11]. The extent of cyto-
keratin (CK)27 positive biliary proliferation has
been suggested to predict native liver survival more
accurately than the extent of liver fibrosis at PE,
while showing a close correlation with the liver
fibrosis stage following successful PE [3,10].
Matrix metalloproteinases (MMPs) and their tissue
inhibitors (TIMPs) are essentially involved with tis-
sue remodeling during hepatic fibrogenesis and can-
cer invasion [12,13]. MMP-7 has been shown to be
upregulated in liver and lung fibrosis, and studies
with a selective MMP-7 inhibitor isofraxidin have
been promising in counteracting progression of fibro-
sis [14–17]. Previous studies have shown significant
alterations in hepatic expression and serum levels of
MMPs and their inhibitors in BA patients at the time
of PE and LTx [15,18–25]. Whether the altered liver
expression occurs secondary to cholestasis remains
unknown, while little is known about expression of
MMPs and TIMPs after successful PE and clearance
of jaundice.
The purpose in this study was to investigate
whether MMPs and TIMPs are involved with pro-
gressive liver damage in BA patients after successful
surgical clearance of jaundice, and whether extent of
liver fibrosis could be assessed for follow-up pur-
poses by measuring their serum concentrations. We
hypothesized that expression of MMP-7 by proliferat-
ing biliary epithelium remains upregulated despite
surgical clearance of biochemical and histological
cholestasis and relates to liver fibrosis. To this end,
expression of MMPs and TIMPs in liver and serum
were evaluated in relation to immunohistochemical
and biochemical markers of liver injury after success-
ful PE.
Materials and methods
Study design
Of the 46 BA patients treated in Helsinki University
Children’s Hospital between May 1991 and June
2011, 27 (59%) patients cleared their jaundice (serum
bilirubin <20 mmol/L). Of them, 25 patients were
enrolled and they underwent liver biopsy and serum
sampling as a part of their clinical follow-up as
described previously [3].
Controls
Control blood samples were obtained from 78 day-
surgery patients (53% males) without evidence of
hepatobiliary disease at median age of 8.5 (interquar-
tile range (IQR) 4.5–14) years. Liver biopsies of 10
children [11 (7.8–15) years] operated for complicated
cholelithiasis with (n5 3) or without underlying liver
disease were used as controls for RNA expression
analyses. Fourteen donor [15 (8–16) years] liver
biopsies were used as controls for immunohistochem-
ical studies. Ten patients with intestinal failure
associated liver disease [4.6 (3.0–8.4) years] with
advanced liver fibrosis were used as disease
controls.
Clinical data
Blood samples were analyzed for platelets, bilirubin,
gamma-glutamyl transferase (GGT), bile acids, ala-
nine aminotransferase, aspartate aminotransferase
(AST) and prealbumin using routine hospital labora-
tory methods. AST to platelet ratio index (APRI) was
calculated [26]. Portal hypertension was defined by
endoscopic verification of oesophageal varices, or the
presence of splenomegaly and thrombocytopenia
(platelet count below 150 3 109/L) at the time of
control biopsy [27]. Splenomegaly was defined as
spleen length over two standard deviations above ref-
erence value of age and gender matched healthy chil-
dren [28].
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Liver biopsies, histological analyses and
cytokeratin-7 immunohistochemistry
An experienced paediatric radiologist performed liver
biopsies percutaneously under ultrasound guidance,
while the patients were anaesthetized for upper gastro-
intestinal endoscopy for variceal surveillance [3]. Core
needle liver biopsies were fixed in formalin, embedded
in paraffin, cut, and stained as previously described [3].
Immunostaining for CK7 was performed using SP52
monoclonal antibody and ultraView Universal DAB
Detection Kit (Ventana, Tuscon, Arizona) for analysis
of bile ductal proliferation (0–2) and staining of peri-
portal hepatocytes (0–4) as described previously [3].
Two experienced paediatric liver pathologists, blinded
to clinical data, reviewed the sections together until a
consensus was reached. Histological features were
assessed according to a semiquantitave scoring system
validated for BA differential diagnostics [29]. Fibrosis
was analyzed by Metavir staging (0–4) and portal
fibrosis was graded separately (05 absent or fibrous
expansions of some portal areas, 15 fibrous expansion
of most portal areas, 25 focal portal-to-portal bridging,
35marked bridging and 45 cirrhosis). Cholestasis
was graded as 0–3. Inflammatory cells in portal areas
(grade 0–3) were analyzed semiquantitatively and,
when present, the percentage of neutrophils, lympho-
cytes and macrophages was counted.
Analyses of serum MMPs and TIMP-1
The concentrations of MMP-7, MMP-9 and TIMP-1
were determined by commercially available enzyme-
linked immune sorbent assay (ELISA) kits as
described previously [30]. The Quantikine
VR
kit for
MMP-7 (R&D Systems, Inc., Minneapolis, MN) and
Biotrak ELISA systems MMP-9 and TIMP-1 (Amer-
sham Biosciences UK, Ltd., Buckinghamshire, UK)
were used according to the manufacturer’s protocol
[30]. MMP-8 analyses were carried out by time-
resolved immunofluorometric assay (Medix Bioche-
mica, Kauniainen, Finland) with the inter assay coef-
ficient of variations (CV%) 7.3% and detection limit
of 0.8 lg/L [31]. The CV% for MMP-7, -9 and
TIMP-1 were 4.4, 8.8 and 13.1%, and detection lim-
its 0.016, 0.6 and 1.25 ng/mL, respectively [30].
RNA isolation and gene expression analysis
Liver tissue specimens were embedded in RNAlater-
solution (Ambion, Life technologies, Thermo Fisher Sci-
entific, Inc., Waltham, MA) and freezed until analyzed.
RNA was extracted using the RNeasy Mini Kit (QIA-
GEN, Frederick, MD). RNA integrity was assessed
spectrophotometrically. Gene expression was analyzed
in triplicate by quantitative real-time polymerase chain
reaction using the Human Fibrosis RT2 ProfilerTM PCR
Array (QIAGEN SABiosciences, Frederick, MD) on an
ABI 7700 Sequence Detection System (Perkin-Elmer
Life Sciences, Boston, MA) according to the manufac-
turer’s instructions. The primer for MMP-7 was a prod-
uct from QIAGEN (Frederick, MD). Quantification of
target gene mRNA expression was performed using the
DDCt method and expressed after normalization to
housekeeping genes (B2M, HPRT1, RPL13A, GAPDH,
ACTB) and relative to control subjects.
Immunohistochemistry of MMP-7 and TIMP-1
For MMP-7 immunohistochemistry, formalin-fixed
and paraffin-embedded liver samples were freshly cut
into 4 mm thick sections, fixed on slides and dried
for 12–24 h at 378C. Subsequently, sections were
deparaffinized in xylene and rehydrated through etha-
nol and distilled water with gradually decreasing con-
centrations. Then slides were treated in a
Pretreatment Module (Lab Vision Corp., Fremont,
CA) in Tris-EDTA buffer (pH 9.0) for 20 min at
988C. Dako REAL EnVision Detection System, Per-
oxidase/DAB1, Rabbit/Mouse (Dako, Glostrup, Den-
mark) was used for staining in Autostainer 480 (Lab
Vision Corp.). Then, slides were incubated with a
monoclonal MMP-7 antibody, clone 141-7B2 (Merck
Millipore, Merck KGaA, Darmstadt, Germany),
diluted 1:1500 in Dako REAL Antibody Diluent
(Dako), for 60 min, followed by a 30 min incubation
with peroxidase-conjugated Dako REAL EnVision/
HRP, Rabbit/Mouse (ENV) Reagent. Slides were
finally visualized by Dao REAL DAB1 Chromogen
for 10 min. Between each step in above-mentioned
procedure, slides were washed with phosphate-
buffered saline containing 0.04% Tween-20 (Dako).
Counterstaining was performed with Meyer’s haema-
toxylin, washed in tap water for 10 min, and
mounted in aqueous mounting medium (Aquamount,
BDH, Poole, UK). For TIMP-1 immunostaining,
same procedure was done with Tris–HCl buffer (pH
8.5) for antigen retrieval and incubating overnight with
a monoclonal TIMP-1 antibody, clone 63515 (R&D
Systems, Minneapolis, MN) with a 1:50 dilution.
Immunohistological analyses were performed by
the primary author (A.K.), using a Leica DM RXA
microscope (Leica Microsystems GmbH, Wetzlar,
Germany) and blinded to other patient data. Immuno-
staining of MMP-7 was confined to bile duct epithe-
lial cells and periportal hepatocytes. The localization
and intensity of MMP-7 immunostaining of biliary
epithelial cells was graded semiquantitatively: no
staining5 0, apical staining5 1, or complete staining
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with weak5 2, moderate5 3 and strong5 4 intensity
(Figure 1). TIMP-1 staining was observed as brown
cytoplasmic particles and graded as follows: 05 no
staining, 15 staining of individual spindle-shaped stro-
mal cells in portal or parenchymal areas, 25 staining
of less than 30% of hepatocytes, 35 over 30% of
hepatocytes. Staining of periportal hepatocytes was
analyzed dichotomously for both MMP-7 and TIMP-1.
Ethics
This study was approved by the Ethics Committee of
the Hospital District of Helsinki and Uusimaa (proto-
col number 345/13/03/03/2008), and complied with
the ethical guidelines of the 1975 Declaration of Hel-
sinki. Informed consent was obtained from all partici-
pating childrens’ legal guardians and adults.
Figure 1. Grading of MMP-7 immunohistochemical expression in biliary epithelial cells (3400). (A) Grade 1: No staining. (B) Grade 2:
Staining only at the apical/luminal side. (C) Grade 3: Biliary epithelial cells completely stained with weak intensity, (D) Grade 4: mod-
erate intensity with staining of periportal hepatocytes (asterisk) and (E) Grade 5: strong intensity.
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Statistical analyses
Unless otherwise stated, the data are expressed as
median and IQR. Statistical analysis was performed
using SPSS software version 21.0 for Windows (IBM
Corp., Armonk, NY). Comparisons between groups
were performed using Mann-Whitney U test for con-
tinuous variables. Fisher’s exact test was used when
comparing dichotomous variables between the
groups. Correlations were calculated using Spear-
man’s rank correlation. Predictive values were per-
ceived as area under the receiver operating
characteristics curves (AUROC). A p value of less
than 0.05 was considered statistically significant.
Results
Patient characteristics and liver histology
Laboratory values and base line clinical patient data
are shown in Table 1. Median age at PE was 62 (41–
88) days and 36% had associated malformations,
including polysplenia, vascular or cardiac anomalies,
situs inversus or malrotation. After median follow-up
time of 3.3 years, median plasma conjugated biliru-
bin concentration was 4 mmol/L and 52% of patients
had developed clinically evident portal hypertension.
Evolution of liver histology is displayed in Table
2. Despite resolution of histological cholestasis and
diminishing portal inflammation after PE, Metavir
fibrosis stage, ductal proliferation and CK-7 positiv-
ity of periportal hepatocytes remained high at follow-
up (Table 2, Figure 2). There was no correlation
between age at follow-up and fibrosis (portal fibrosis:
r520.112, p5 0.594; Metavir stage: r520.025,
p5 0.906).
Hepatic gene expression of MMPs and TIMPs
As presented in Table 3, BA patients showed signifi-
cantly increased hepatic RNA expression of MMP-7
(29-fold, p< 0.001), MMP-2 (3.1-fold, p< 0.001)
and MMP-14 (1.7-fold, p5 0.007), when compared
to controls. Of MMP tissue inhibitors only TIMP-1
(1.8-fold, p< 0.001) gene expression was increased.
There was a positive correlation between the liver
gene expression of MMP-7 and TIMP-1 (r5 0.531,
p5 0.008) among patients, but not among controls
(r5 0.006, p5 0.987).
Upregulated liver expression of MMP-7 localizes
in biliary epithelium and periportal hepatocytes,
similar to CK-7
As shown in Figure 3, expression of MMP-7 was sig-
nificantly increased in biliary epithelium of bile ducts
and proliferating ductules when compared to controls.
In most patients (56%) biliary epithelial cells com-
pletely stained with moderate or strong intensity. In
control specimens, staining was restricted to the api-
cal cytoplasm without any detectable staining in five
Table 1. Patient characteristics
Number of patients 25
Age at portoenterostomy (months) 2.0 (1.3–2.9)
Male gender, n (%) 13 (52%)
Associated anomalies, n (%) 9 (36%)
Age at follow-up (years)
Splenomegaly at follow-up, n (%)
3.3 (2.1–7.4)
9 (36%)
Portal hypertension at follow-up, n (%) 13 (52%)
Liver biochemistry at follow-up
Bilirubin total (lmol/L) 10 (4–17)
Bilirubin direct (conjugated) (lmol/L) 4 (2–7)
Gamma-glutamyl transferase (GGT) (U/L) 51 (24–156)
Bile acids, total (lmol/L) 32 (18–87)
Prealbumin (mg/L) 146 (115–169)
Alanine aminotransferase (ALT) (U/L) 41 (24–88)
APRI* 1.17 (0.43–1.93)
Data are median (interquartile range) or frequency (%).
*APRI, [(Aspartate aminotransferase (AST, U/L)/50)/Platelet count (E9/L)] 3 100.
Table 2. Liver histology at portoenterostomy and after follow-up of median 3.3 years
HISTOLOGY Scale Portoenterostomy (n5 20) Follow-up (n5 25) p value
Portal fibrosis 0–4 3 (2–3) 3 (2–4) 0.480
Metavir fibrosis 0–4 2 (2–3) 3 (2–4) 0.088
Intracellular cholestasis 0–3 2 (1–3) 0 (0–0) <0.001
Intracanalicular cholestasis 0–3 2 (1–3) 0 (0–0) <0.001
Bile ductular cholestasis 0–3 1 (0–2) 0 (0–0) 0.002
Ductal proliferation* 0–2 1 (1–2) 1 (1–1) 0.302
Cytokeratin-7 expression of periportal hepatocytes 0–4 1 (1–2) 1 (0–4) 0.014
Portal inflammatory cell infiltrate 0–3 2 (2–3) 1 (0–1) <0.001
Lymphocytes (%) 50 (20–80) 70 (0–90) 0.304
Neutrophils (%) 25 (5–60) 0 (0–5) 0.005
Macrophages (%) 10 (5–20) 5 (0–5) 0.005
Data are median (interquartile range). Significance was evaluated by Wilcoxon Signed Rank Test.
*Ductal proliferation was analyzed using cytokeratin-7-immunostaining.
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(36%). Expression of TIMP-1 did not differ between
BA patients and controls (2 vs 2, p5 0.189). Among
patients, biliary MMP-7 expression correlated posi-
tively with liver MMP-7 RNA expression (r5 0.453,
p5 0.026). Similar to MMP-7 immunostaining of
CK-7 localized in biliary epithelium of bile ducts and
ductal proliferations, and in periportal hepatocytes
(Figure 4). Biliary epithelial MMP-7 expression cor-
related positively with ductal proliferation (r5 0.454,
p5 0.023), and periportal MMP-7 staining of hepato-
cytes associated with CK-7 positive periportal hepa-
tocytes (Figure 4). MMP-7 expression of biliary
epithelium was increased in patients with MMP-7
positive periportal hepatocytes (4 vs 2, p5 0.046).
Patients with CK-7 positive periportal hepatocytes
had also significantly increased biliary epithelial
staining of MMP-7 (3 vs 2, p5 0.002).
Increased serum levels of MMP-7 and TIMP-1
reflected their enhanced liver expression
As presented in Table 4, in comparison to control
subjects, BA patients had significantly higher serum
levels of MMP-7 (sixfold, p< 0.001) and TIMP-1
(p< 0.001) and lower levels of MMP-9 (p< 0.001).
In patients, serum levels of MMP-7 correlated posi-
tively with MMP-7 RNA expression (r5 0.548,
p5 0.007) and immunohistochemical MMP-7 expres-
sion in biliary epithelium (r5 0.532, p5 0.007). A
respective positive correlation was also seen between
Figure 2. After successful portoenterostomy (PE), fibrosis and ductal proliferation increased while cholestasis resolved. Liver histology
from the same patient at PE and 2 years after successful PE (3200). (A) At PE, portal fibrosis grade 3 (0–4), Metavir stage 2 (0–4)
and intracellular cholestasis grade 3 (0–3). (B) At PE, CK-7 positive biliary proliferation grade 1 (0–2, asterisk). (C) At follow-up fibro-
sis progressed (both portal fibrosis grade and Metavir stage 4) and intracellular cholestasis resolved. (D) At follow-up, CK-7 staining
demonstrated increased ductal proliferation (grade 2, asterisk) and CK-7 staining of periportal hepatocytes (grade 4, (0–4), arrow)
indicating hepatocyte-to-cholangiocyte metaplasia.
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serum TIMP-1 and TIMP-1 RNA expression
(r5 0.451, p5 0.027). Among patients, there was a
strong positive correlation between serum levels of
MMP-7 and TIMP-1 (r5 0.600, p5 0.002), which
was weaker among controls (r5 0.225, p5 0.047).
Increased expression of MMP-7 in biliary
epithelium and serum was coupled with liver
fibrosis
Patients with Metavir stage 1 fibrosis (n5 6) had sig-
nificantly weaker MMP-7 staining of biliary epithe-
lial cells than patients with more advanced fibrosis (1
vs 3, p5 0.005). As shown in Figure 5, there was a
positive correlation between biliary epithelial MMP-7
expression and Metavir fibrosis stage (r5 0.605,
p5 0.001), portal fibrosis grade (r5 0.606,
p5 0.001) and portal inflammatory cell infiltrate
(r5 0.694, p< 0.001). The patients without portal
fibrosis (n5 4) had significantly lower serum MMP-
7 levels when compared to patients with portal fibro-
sis (5.78 vs 17.6 ng/mL, p5 0.008). Serum MMP-7
showed significant predictive value for portal fibrosis
with AUROC of 0.925 (CI 95%: 0.817–1.000,
p5 0.008, Figure 5).
Patients with established histological cirrhosis
(Metavir stage 4, n5 9) showed increased hepatic
gene expression of TIMP-1 (1.7-fold, p5 0.014) and
MMP-2 (1.7-fold, p5 0.05) and biliary epithelial
expression of MMP-7 (3 vs 2, p5 0.053), when com-
pared to those without cirrhosis. Upregulated TIMP-1
gene expression also correlated positively with Meta-
vir fibrosis stage (r5 0.449, p5 0.028) and portal
fibrosis grade (r5 0.482, p5 0.017), as did MMP-2
(r5 0.483, p5 0.017 and r5 0.454, p5 0.026,
respectively). Liver gene expression (1.5-fold,
p5 0.019) and serum level (194 vs 126 ng/mL,
p5 0.004) of TIMP-1 was increased in patients with
portal hypertension (n5 13) in relation to those
without.
Correlations of MMP-7 and TIMP-1 with
biochemical cholestasis and liver function
MMP-7 expression in biliary epithelium correlated
positively with plasma conjugated bilirubin
(r5 0.514, p5 0.009) and bile acids (r5 0.639,
p5 0.001). Similarly, plasma bile acids (r5 0.502,
p5 0.012) and conjugated bilirubin (r5 0.449,
p5 0.028) correlated positively, and prealbumin neg-
atively (r520.526, p5 0.008), with serum MMP-7
concentration.
Overexpression of TIMP-1 RNA correlated posi-
tively with plasma levels of conjugated bilirubin
(r5 0.779, p< 0.001), bile acids (r5 0.564,
p5 0.005) and APRI (r5 0.556, p5 0.005), and neg-
atively with plasma prealbumin (r520.692,
p< 0.001). Similarly, plasma bile acids (r5 0.696,
p< 0.001) and conjugated bilirubin (r5 0.569,
p5 0.003) were positively related to serum TIMP-1,
and negatively to prealbumin (r520.637,
p5 0.001). APRI correlated positively with serum
TIMP-1 (r5 0.486, p5 0.014).
MMP-7 overexpression is unique for BA
Intestinal failure patients with comparable Metavir
fibrosis stage [2 (2–2) vs 3 (2–4), p5 0.247] showed
substantially lower hepatic RNA expression [2.7
(1.2–4.0)-fold vs 29 (6.1–70)-fold, p< 0.001], immu-
nohistological staining [grade 1 (0–1) vs 3 (2–3),
p< 0.001], and serum levels [3.09 (2.10–4.44) vs
14.4 (7.01–28.6) ng/mL, p< 0.001] of MMP-7 than
BA patients. Metavir stage showed no correlation
with hepatic gene expression (r520.174,
p5 0.631), protein expression (r5 0.272, p5 0.447)
or serum levels (r5 0.290, p5 0.416) of MMP-7 in
intestinal failure patients.
Discussion
In this study, we have systematically assessed the
expression of MMPs and their tissue inhibitors in BA
following successful surgical clearance of jaundice
by PE. Identification of the molecular mechanisms
driving advancing liver fibrosis after successful PE
would potentially offer a possibility to hinder pro-
gression of liver injury and extend native liver sur-
vival by postoperative pharmacological manipulation
Table 3. Hepatic gene expression of MMPs and TIMPs in
patients and controls
Controls (N5 10) Patients (N5 24) P value
MMP-1 1.00 (0.92–1.55) 0.90 (0.74–1.11) 0.597
MMP-2 1.00 (0.81–1.10) 3.12 (2.26–4.01) <0.001
MMP-3 1.00 (0.85–1.37) 0.77 (0.63–0.95) 0.273
MMP-7 1.00 (0.80–1.90) 29.2 (6.11–70.3) <0.001
MMP-8 1.00 (0.92–1.55) 0.90 (0.74–1.13) 0.650
MMP-9 1.00 (0.57–1.52) 1.25 (0.78–2.45) 0.186
MMP-13 1.00 (0.92–1.55) 0.90 (0.74–1.11) 0.623
MMP-14 1.00 (0.76–1.18) 1.70 (1.16–2.20) 0.007
TIMP-1 1.00 (0.83–1.23) 1.80 (1.52–2.93) <0.001
TIMP-2 1.00 (0.79–1.02) 1.05 (0.90–1.32) 0.623
TIMP-3 1.00 (0.62–1.37) 0.72 (0.54–1.06) 0.273
TIMP-4 1.00 (0.92–1.62) 0.87 (0.69–1.10) 0.650
Data are median (interquartile range). Transcript levels are expressed after
normalization to housekeeping genes and relative to control subjects using
the DDCt method. Significance between groups was evaluated by Mann-
Whitney U test.
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[16,32]. Our major findings show, first, that of the
various MMPs and their inhibitors, liver expression
of MMP-7 was the one mainly upregulated after suc-
cessful PE and that this substantial overexpression
was unique for BA. Second, the increased MMP-7
liver expression principally localized in the biliary
epithelium of the bile ducts and ductular prolifera-
tions, but also in periportal hepatocytes with similar
expression pattern to CK-7. Third, hepatic MMP-7
overexpression correlated with its markedly increased
serum levels, and both associated with the liver fibro-
sis stage, which was not observed among intestinal
failure patients with comparable liver fibrosis. Col-
lectively, these findings suggest that MMP-7 may be
uniquely involved in tissue remodeling during pro-
gression of liver injury after successful PE despite
effective clearance of biochemical and histological
jaundice, and that serum MMP-7 may be a valuable
prognostic follow-up tool in BA.
Besides being expressed by developing fetal
human liver, MMP-7 is involved with progression of
liver fibrosis and overexpressed in various liver can-
cers, including cholangiocarcinoma and hepatocellu-
lar carcinoma [14,33–36]. In rhesus rotavirus infected
rats, an animal model of BA, liver expression of
MMP-7 is increased [37]. In several previous studies,
hepatic gene expression of MMP-7 has been shown
to be upregulated both at the time of PE and LTx,
implicating its potential role in liver fibrogenesis in
BA [15,18–21]. It should be emphasized that at these
extreme stages of the disease the majority of patients
are severely cholestatic. Intriguingly, we found
marked gene and protein overexpression of MMP-7
also after effective surgical clearance of biochemical
and histological cholestasis by successful PE. Only
one previous study has explored protein expression
of MMP-7 in BA, where the patients were studied at
PE and LTx [15]. Similar to our findings, MMP-7
expression localized mainly in biliary epithelial cells
and hepatocytes, but also in endothelial cells and
local macrophages (Kupffer cells). As liver fibrosis
progressed from PE to LTx, staining intensity of
hepatocytes and especially biliary epithelium
increased [15]. Here, a positive correlation between
Figure 3. Following successful portoenterostomy (PE) biliary epi-
thelial protein expression of matrix metalloproteinase (MMP)-7
was significantly increased when compared to controls. (A)
Immunostaining of a control specimen showing weak luminal
staining (grade 1) of bile duct epithelial cells in the portal area
(3400). (B) Enhanced epithelial MMP-7 immunostaining (grade
4) of biliary proliferation three years after successful PE (3400).
(C) Biliary epithelial expression of MMP-7 was significantly
increased in patients (n5 25) when compared to controls
(n5 14). Box plots display median (bold transverse line), inter-
quartile range (rectangle) and range. Significance evaluated by
Mann-Whitney U test.
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MMP-7 expression in biliary epithelial cells and
Metavir fibrosis stage and portal fibrosis grade was
found, while serum MMP-7 strongly predicted pres-
ence of portal fibrosis. Collectively, these data sug-
gest that MMP-7 is essentially involved with
progression of liver fibrosis also after successful PE,
offering a potential therapeutic target to extend native
liver survival by inhibition of MMP-7 hyperactivity
[16,32]. Preliminary in vitro studies with a selective
MMP-7 inhibitor isofraxidin have been promising,
while inhibition of MMP hyperactivity in cystic chol-
angiocytes decreases cystic biliary deformation and
fibrosis in polycystic liver disease [16,32].
The increased expression of MMP-7 localized in
the biliary epithelial cells of the bile ducts and ductal
proliferations, but also in periportal hepatocytes simi-
lar to CK-7 expression. Cytokeratin-7 is a cytos-
keletal protein expressed by bile duct epithelial cells,
intermediate hepatobiliary cells of ductular prolifera-
tions but not by normal hepatocytes. Ductular and
biliary transformation of periportal hepatocytes, inter-
preted by CK-7 staining among specific hepatocyte
Figure 4. MMP-7 and CK-7 expression localized in biliary epithelium and periportal hepatocytes after successful portoenterostomy
(PE). (A) CK-7 and (B) MMP-7 stained biliary epithelium (asterisks) and periportal hepatocytes (arrows) in the same patient; CK-7
positive ductal proliferation grade 2 (scale 0–2) and MMP-7 staining grade 3 (0–4) (3400, inserts 3200). (C) Patients with MMP-7
expression in periportal hepatocytes (n5 4) had significantly increased CK-7 expression in periportal hepatocytes when compared to
those without (n5 21). Significance evaluated by Mann-Whitney U test. (D) Biliary epithelial MMP-7 staining correlated positively
with CK-7 positive ductal proliferation. Spearman’s rank correlation (n5 25). Box plots display median (bold transverse line), inter-
quartile range (rectangle) and range.
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markers, has been demonstrated in vivo [7,38,39].
Here, overexpression of MMP-7 and CK-7 shared
similar patterns in ductal proliferation and in peripor-
tal hepatocytes, suggesting that MMP-7 is involved
with hepatic tissue remodeling by ductal proliferation
in BA. MMP-7 is able to cleave extracellular matrix
and basement membrane, while ductal proliferation
may drive fibrogenesis through epithelial-to-
mesenchymal metaplasia [8,9,12,14,17,40].
Activated hepatic stellate cells produce TIMP-1,
modulating liver fibrogenesis by inhibition of MMPs
and by antiapoptotic and proliferating effects inde-
pendent of MMP interactions [5,17,41]. In previous
BA studies, gene expression and serum levels of
TIMP-1 have been shown to be upregulated in
patients with end-stage cirrhosis compared to healthy
controls [20,22,23]. Controversially, others have
found no correlation between gene or protein expres-
sion of TIMP-1 and different stages of fibrosis at the
time of PE [24,25]. In our study, increased hepatic
gene expression of TIMP-1 associated with advanced
histological liver fibrosis, established cirrhosis, APRI
and portal hypertension. These findings suggest that
TIMP-1 contributes to hepatic tissue remodeling and
fibrotic change along with MMP-7 following success-
ful PE. MMP-14 is able to activate MMP-2 on cell
membranes, having both anti-fibrogenic and pro-
fibrogenic effects [17,42]. Here, gene expression of
MMP-2 and MMP-14 was modestly increased in BA
compared to control subjects, while MMP-2 expres-
sion correlated positively with liver fibrosis.
Our findings also implicate that serum MMP-7
might be a useful biomarker for fibrosis and liver
injury in BA. Serum MMP-7 concentration positively
correlated with gene and protein expression in the
liver. Both increased serum concentration and biliary
epithelial expression of MMP-7 was related to liver
fibrosis, while serum MMP-7 accurately predicted
presence of portal fibrosis. Further prospective stud-
ies are required to confirm these findings.
This study had limitations. The age range of the
patients was relatively wide and the number of
patients studied limited. However, to our best knowl-
edge, this is one of the first studies to systematically
explore the molecular mechanisms underlying the
progressive liver damage after successful PE.
In conclusion, our findings support an important
role of altered gene and protein expression of MMP-
7 in the progression of liver fibrosis and tissue
remodeling after successful surgical clearance of
Figure 5. Liver expression of MMP-7 is coupled with fibrosis.
(A) Biliary epithelial MMP-7 expression correlated positively
with Metavir fibrosis stage after successful portoenterostomy.
Box plots display median (bold transverse line), interquartile
range (rectangle) and range. Spearman’s rank correlation
(n5 25). (B) Area under the receiver operating characteristics
curve (AUROC) showing predictive value of serum MMP-7 for
histological portal fibrosis after successful portoenterostomy.
Table 4. Serum MMP and TIMP concentrations
Patients (N5 25) Controls (N5 78) P value
MMP-7 (ng/mL) 14.4 (7.01–28.6) 2.23 (1.60–2.88) <0.001
MMP-8 (ng/mL) 45.8 (33.6–96.7) 36.4 (18.7–69.9) 0.047
MMP-9 (ng/mL) 114 (66.5–206) 373 (270–541) <0.001
TIMP-1 (ng/mL) 139 (121–195) 88.0 (69.6–103) <0.001
Data are median (interquartile range). Significance was evaluated by Mann-
Whitney U test.
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jaundice and may introduce a potential therapeutic
target to pharmacologically extend native liver sur-
vival after PE. Further studies are needed to evaluate
effects of MMP-7 inhibition on progression of liver
injury after PE.
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